Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.

Maya Koren-Michowitz, Hannah Maayaan, Ronit Yerushalmi, Noga Shem-Tov, Yulia Volchek, Abraham Avigdor, Avichai Shimoni, Arnon Nagler

Blood (2012) 120 (21): 2629.

https://doi.org/10.1182/blood.V120.21.2629.2629

Published: 2012

Journal Articles

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Rosa Ruchlemer, MD, Deborah Elstein, PhD, Eti Broide, Constantine Reinus, Hannah Maayaan, Ari Zimran, MD

Blood (2011) 118 (21): 1100.

https://doi.org/10.1182/blood.V118.21.1100.1100

Published: 2011

Journal Articles

Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning.

Avichai Shimoni, Avital Rand, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, Hannah Maayaan, Ronit Yerushalmi, Arnon Nagler

Blood (2009) 114 (22): 518.

https://doi.org/10.1182/blood.V114.22.518.518

Published: 2009

Journal Articles

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, Noga Shem-Tov, MD, Izhar Hardan, Yulia Volchek, MD, Hannah Maayaan, MD, Ronit Yerushalmi, Arnon Nagler, MD

Blood (2009) 114 (22): 2255.

https://doi.org/10.1182/blood.V114.22.2255.2255

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation.

Avichai Shimoni, Avital Rand, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, Hannah Maayaan, Ronit Yerushalmi, Arnon Nagler

Blood (2009) 114 (22): 3358.

https://doi.org/10.1182/blood.V114.22.3358.3358

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning.

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning.

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only